Selective persistence of dermal CD8+ T cells in lesional plaque psoriasis after clobetasol-17 propionate treatment

Acta Dermato-Venereologica

Volumn 85, Issue 2, 2005, Pages 113-117

  Bovenschen, H Jorn ^a   Vissers, Wynand H P M ^a   Seyger, Marieke M B ^a   Van De Kerkhof, Peter C M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Corticosteroids; Epidermal proliferation; Psoriasis; T cell subsets

Indexed keywords

CD2 ANTIGEN; CD4 ANTIGEN; CD45RO ANTIGEN; CD8 ANTIGEN; CLOBETASOL PROPIONATE; CORTICOSTEROID; KI 67 ANTIGEN;

ADULT; ARTICLE; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DERMIS; DISEASE SEVERITY; DRUG POTENCY; FEMALE; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; LYMPHOCYTIC INFILTRATION; MALE; PRIORITY JOURNAL; PSORIASIS; PUNCH BIOPSY; QUANTITATIVE ANALYSIS; RELAPSE; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION;

ADMINISTRATION, CUTANEOUS; ANTI-INFLAMMATORY AGENTS; CD8-POSITIVE T-LYMPHOCYTES; CLOBETASOL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PSORIASIS; SEVERITY OF ILLNESS INDEX; T-LYMPHOCYTE SUBSETS;

EID: 16444375448     PISSN: 00015555     EISSN: None     Source Type: Journal    
DOI: 10.1080/00015550410024968     Document Type: Article

References (37)

1. Krueger JG. The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol 2002; 46: 1-23.
2. Gudjonsson JE, Johnston A, Sigmundsdottir H, Valdimarsson H. Immunopathogenic mechanisms in psoriasis. Clin Exp Immunol 2004; 135: 1-8.
3. Prinz JC. Psoriasis vulgaris - a sterile antibacterial skin reaction mediated by cross-reactive T cells? An immunological view of the pathophysiology of psoriasis. Clin Exp Dermatol 2001; 26: 326-332.
4. Barker JN, Mitra RS, Griffiths CE, Dixit VM, Nickoloff BJ. Keratinocytes as initiators of inflammation. Lancet 1992; 337: 211-214.
5. Valdimarsson H, Baker BS, Jonsdottir I, Fry L. Psoriasis: a disease of abnormal proliferation induced by T lymphocytes. Immunol Today 1986; 7: 256-259.
6. Bos JD, Hulsebosch HJ, Krieg SR, Bakker PM, Cormane RH. Immunocompetent cells in psoriasis. In situ immunophenotyping by monoclonal antibodies. Arch Dermatol Res 1983; 275: 181-189.
7. Nickoloff BJ. The immunologic and genetic basis of psoriasis. Arch Dermatol 1999; 135: 1104-1110.
8. Asadullah K, Volk HD, Sterry W. Novel immunotherapies for psoriasis. Trends Immunol 2002; 23: 47-53.
9. Boehncke WH. Immunomodulatory drugs for psoriasis. BMJ 2003; 327: 634-635.
10. Ellis CN, Krueger GG. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med 2001; 345: 248-255.
11. Gottlieb A. Immunobiologic agents for the treatment of psoriasis: clinical research delivers new hope for patients with psoriasis. Arch Dermatol 2003; 139: 791-793.
12. Krueger GG, Ellis CN. Alefacept therapy produces remission for patients with chronic plaque psoriasis. Br J Dermatol 2003; 148: 784-788.
13. Prinz JC. Which T cells cause psoriasis? Clin Exp Dermatol 1999; 24: 291-295.
14. Menssen A, Trommler P, Vollmer S, Schendel D, Albert E, Gurtler L, et al. Evidence for an antigen-specific cellular immune response in skin lesions of patients with psoriasis vulgaris. J Immunol 1995; 155: 4078-4083.
15. Sanders ME, Makgoba MW, Sharrow SO, Stephany D, Springer TA, Young HA, et al. Human memory T lymphocytes express increased levels of three cell adhesion molecules (LFA-3, CD2, and LFA-1) and have three other molecules (UCHL1, CDw29, and Pgp-1) and have enhanced IFN-γ production. J Immunol 1988; 140: 1401-1407.
16. Wallace DL, Beverley PC. Phenotypic changes associated with activation of CD45RA+ and CD45RO+ T cells. Immunology 1990; 69: 460-467.
17. Valdimarsson H, Baker BS, Jonsdottir I, Powles A, Fry L. Psoriasis: a T-cell-mediated autoimmune disease induced by streptococcal superantigens? Immunol Today 1995; 16: 145-149.
18. Prinz JC, Gross B, Vollmer S, Trommler P, Strobel I, Meurer M, et al. T cell clones from psoriasis skin lesions can promote keratinocyte proliferation in vitro. Eur J Immunol 1994; 24: 593-598.
19. Bata-Csorgo Z, Hammerberg C, Voorhees JJ, Cooper KD. Kinetics and regulation of human keratinocyte stem cell growth in short-term primary ex vivo culture. Cooperative growth factors from psoriatic lesional T lymphocytes stimulate proliferation among psoriatic uninvolved, but not normal, stem keratinocytes. J Clin Invest 1995; 95: 317-327.
20. Castelijns FA, Gerritsen MJ, van Erp PE, Van de Kerkhof PCM. Cell-kinetic evidence for increased recruitment of cycling epidermal cells in psoriasis: the ratio of histone and Ki-67 antigen expression is constant. Dermatology 2000; 201: 105-110.
21. Van Erp PE, de Mare S, Rijzewijk JJ, Van de Kerkhof PC, Bauer FW. A sequential double immunoenzymic staining procedure to obtain cell kinetic information in normal and hyperproliferative epidermis. Histochem J 1989; 21: 343-347.
22. Falkenstein E, Tillmann HC, Christ M, Feuring M, Wehling M. Multiple actions of steroid hormones - a focus on rapid, noneenomic effects. Pharmacol Rev 2000; 52: 513-556.
23. Ashwell JD, Lu FW, Vacchio MS. Glucocorticoids in T cell development and function. Annu Rev Immunol 2000; 18: 309-345.
24. Almawi WY, Lipman ML, Stevens AC, Zanker B, Hadro ET, Strom TB. Abrogation of glucocorticoid-mediated inhibition of T-cell proliferation by the synergistic action of IL-1, IL-6, and IFN-gamma. J Immunol 1991; 146: 3253-3257.
25. Al-Daraji WI, Grant KR, Ryan K, Saxton A, Reynolds NJ. Localization of calcineurin/NFAT in human skin and psoriasis and inhibition of calcineurin/NFAT activation in human keratinocytes by cyclosporine A. J Invest Dermatol 2002; 118: 779-788.
26. Eisman S, Rustin MH. Corticosteroids. In: Van de Kerkhof PCM, ed. Textbook of psoriasis, 2nd edn. Oxford: Blackwell Publishing, 2003.
27. Bos JD, Krieg SR. Psoriasis infiltrating cell immunophenotype: changes induced by PUVA or corticosteroid treatment in T-cell subsets, Langerhans' cells and interdigitating cells. Acta Derm Venereol 1985; 65: 390-397.
28. Ashworth J, Booker J, Breathnach SM. Effects of topical corticosteroid therapy on Langerhans cell antigen presenting function in human skin. Br J Dermatol 1988; 118: 457-469.
29. Fisher LB, Maibach HI, The effect of corticosteroids on human epidermal mitotic activity. Arch Dermatol 1971; 103: 39-41.
30. Marks R, Halprin K, Fukui K. Topically applied triamcinolone and macromolecular synthesis by human epidermis. J Invest Dermatol 1971; 56: 470-478.
31. De Jong EM, Ferrier CM, de Zwart A, Wauben-Penris PJ, Korstanje C, Van de Kerkhof PC. Effects of topical treatment with budesonide on parameters for epidermal proliferation, keratinization and inflammation in psoriasis. J Dermatol Sci 1995; 9: 185-194.
32. Vissers WH, Berends M, Muys L, Van Erp PE, De Jong EM, Van de Kerkhof PC. The effect of the combination of calcipotriol and betamethasone dipropionate versus both monotherapies on epidermal proliferation, keratinization and T-cell subsets in chronic plaque psoriasis. Exp Dermatol 2004; 13: 106-112.
33. Lamba S, Lebwohl M. Combination therapy with vitamin D analogues. Br J Dermatol 2001; 144(Suppl 58): 27-32.
34. Lebwohl M. Topical application of calcipotriene and corticosteroids: combination regimens. J Am Acad Dermatol 1997; 37: S55-S58.
35. Lebwohl M, Siskin SB, Epinette W, Breneman D, Funicella T, Kalb R, et al. A multicenter trial of calcipotriene ointment and halobetasol ointment compared with either agent alone for the treatment of psoriasis. J Am Acad Dermatol 1996; 35: 268-269.
36. Nickoloff BJ, Wrone-Smith T. Injection of pre-psoriatic skin with CD4+ T cells induces psoriasis. Am J Pathol 1999; 155: 145-158.
37. Kursar M, Bonhagen K, Fensterle J, Kohler A, Hurwitz R, Kamradt T, et al. Regulatory CD4+CD25+ T cells restrict memory CD8+ T cell responses. J Exp Med 2002; 196: 1585-1592.